Literature DB >> 34232790

Effect of Withdrawing Chronic Topical Immune Modulating Treatment on Schirmer Tear Test Values in Dogs with Dry Eye Disease: Relevance to Dry Eye Studies.

Shin Ae Park1,2, Kathryn L Good1, Sara M Thomasy1,3, Philip H Kass4, Christopher J Murphy1,3.   

Abstract

Purpose: To determine the effect of discontinuing chronic topical immune modulating (IM) treatment on Schirmer tear test (STT) values in dogs with dry eye disease (DED).
Methods: Serial measurements of STTs from 14 dogs (16 eyes) previously diagnosed with DED were obtained before and after discontinuation of topical IM agents. Dogs with moderate to severe DED that had been well controlled with a topical IM treatment were included. After initial assessment topical IM treatment was discontinued, but topical lubricant was continued, and STT values were obtained sequentially. A mixed-effects regression model was used to evaluate the effects of age, gender, breed, clinical score, frequency of treatment, baseline STT value, and drug type on final STT values after IM withdrawal. P < 0.05 was considered statistically significant.
Results: During the follow-up period after the IM treatment had been discontinued (136 ± 29 days), 50% of the eyes (n = 8) exhibited STT values that never decreased to <10 mm/min. In the other 50% (n = 8), STT values decreased from 15.9 ± 4.7 mm/min to 6.1 ± 0.9 mm/min. In this group, the time it took to decrease the STT to <10 mm/min was 21.1 ± 9.5 days. Severe clinical signs of DED and low baseline STT pre-IM treatment significantly affected STT post-IM treatment withdrawal (P < 0.05). Conclusions: The duration that a residual effect of topical IM treatment persists needs to be taken into consideration when studies are designed utilizing dogs with previous IM treatment for DED.

Entities:  

Keywords:  DED; cyclosporine; discontinue; immune-mediated; tacrolimus; washout

Mesh:

Substances:

Year:  2021        PMID: 34232790      PMCID: PMC8558070          DOI: 10.1089/jop.2021.0033

Source DB:  PubMed          Journal:  J Ocul Pharmacol Ther        ISSN: 1080-7683            Impact factor:   2.850


  13 in total

1.  Topical administration of cyclosporine for treatment of keratoconjunctivitis sicca in dogs.

Authors:  R V Morgan; K L Abrams
Journal:  J Am Vet Med Assoc       Date:  1991-10-15       Impact factor: 1.936

2.  Effect of topical 0.02% tacrolimus aqueous suspension on tear production in dogs with keratoconjunctivitis sicca.

Authors:  Andrew Berdoulay; Robert V English; Brad Nadelstein
Journal:  Vet Ophthalmol       Date:  2005 Jul-Aug       Impact factor: 1.644

Review 3.  Characteristics of a canine model of KCS: effective treatment with topical cyclosporine.

Authors:  R Kaswan
Journal:  Adv Exp Med Biol       Date:  1994       Impact factor: 2.622

4.  Cellular immunity in dogs with keratoconjunctivitis sicca before and after treatment with topical 2% cyclosporine.

Authors:  B C Gilger; J Andrews; D A Wilkie; M Wyman; M D Lairmore
Journal:  Vet Immunol Immunopathol       Date:  1995-12       Impact factor: 2.046

5.  The pharmacologic assessment of a novel lymphocyte function-associated antigen-1 antagonist (SAR 1118) for the treatment of keratoconjunctivitis sicca in dogs.

Authors:  Christopher J Murphy; Ellison Bentley; Paul E Miller; Kim McIntyre; Gary Leatherberry; Richard Dubielzig; Elizabeth Giuliano; Cecil P Moore; Thomas E Phillips; Peter B Smith; Elizabeth Prescott; Jacqueline M Miller; Peter Thomas; Randall Scagliotti; Doug Esson; Tom Gadek; Charles A O'Neill
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-05-16       Impact factor: 4.799

6.  The effect of topical pimecrolimus on keratoconjunctivitis sicca and chronic superficial keratitis in dogs: results from an exploratory study.

Authors:  Barbara Nell; Ingo Walde; Andreas Billich; Peter Vit; Josef G Meingassner
Journal:  Vet Ophthalmol       Date:  2005 Jan-Feb       Impact factor: 1.644

7.  Clinical evaluation of pimecrolimus eye drops for treatment of canine keratoconjunctivitis sicca: a comparison with cyclosporine A.

Authors:  Ron Ofri; George N Lambrou; Ingrid Allgoewer; Uwe Graenitz; Teresa M Pena; Bernhard M Spiess; Elisabeth Latour
Journal:  Vet J       Date:  2007-10-22       Impact factor: 2.688

Review 8.  Immunopathogenesis of keratoconjunctivitis sicca in the dog.

Authors:  David L Williams
Journal:  Vet Clin North Am Small Anim Pract       Date:  2008-03       Impact factor: 2.093

9.  Keratoconjunctivitis sicca: immunological evaluation of 62 canine cases.

Authors:  R L Kaswan; C L Martin; D L Dawe
Journal:  Am J Vet Res       Date:  1985-02       Impact factor: 1.156

10.  An investigation comparing the efficacy of topical ocular application of tacrolimus and cyclosporine in dogs.

Authors:  Diane V H Hendrix; Elizabeth A Adkins; Daniel A Ward; Jamie Stuffle; Brian Skorobohach
Journal:  Vet Med Int       Date:  2011-05-23
View more
  1 in total

1.  Topical applications of allogeneic adipose-derived mesenchymal stem cells ameliorate the canine keratoconjunctivitis sicca.

Authors:  Li-Ning Wei; Ching-Ho Wu; Chung-Tien Lin; I-Hsuan Liu
Journal:  BMC Vet Res       Date:  2022-06-10       Impact factor: 2.792

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.